RNLX vs. ONDS, GAN, REFR, EGIO, LPSN, CUTR, PHUN, LPTH, CMTL, and INUV
Should you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Ondas (ONDS), GAN (GAN), Research Frontiers (REFR), Edgio (EGIO), LivePerson (LPSN), Cutera (CUTR), Phunware (PHUN), LightPath Technologies (LPTH), Comtech Telecommunications (CMTL), and Inuvo (INUV). These companies are all part of the "computer and technology" sector.
Renalytix (NASDAQ:RNLX) and Ondas (NASDAQ:ONDS) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations.
Renalytix presently has a consensus price target of $5.00, indicating a potential upside of 874.47%. Ondas has a consensus price target of $2.75, indicating a potential upside of 257.14%. Given Renalytix's higher possible upside, research analysts clearly believe Renalytix is more favorable than Ondas.
Ondas has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Ondas, indicating that it is currently the more affordable of the two stocks.
Ondas received 8 more outperform votes than Renalytix when rated by MarketBeat users. Likewise, 48.48% of users gave Ondas an outperform vote while only 32.00% of users gave Renalytix an outperform vote.
In the previous week, Renalytix and Renalytix both had 7 articles in the media. Ondas' average media sentiment score of -0.25 beat Renalytix's score of -0.38 indicating that Ondas is being referred to more favorably in the news media.
9.9% of Renalytix shares are owned by institutional investors. Comparatively, 37.7% of Ondas shares are owned by institutional investors. 18.3% of Renalytix shares are owned by company insiders. Comparatively, 4.6% of Ondas shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Ondas has a net margin of -307.07% compared to Renalytix's net margin of -1,687.80%. Ondas' return on equity of -108.29% beat Renalytix's return on equity.
Renalytix has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, Ondas has a beta of 2.67, meaning that its stock price is 167% more volatile than the S&P 500.
Summary
Ondas beats Renalytix on 11 of the 16 factors compared between the two stocks.
Get Renalytix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renalytix Competitors List
Related Companies and Tools
